Post-transcriptional regulation of interferons and their signaling pathways

Journal of Interferon and Cytokine Research

Volumn 34, Issue 5, 2014, Pages 318-329

  Savan, Ram ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; BETA INTERFERON; GAMMA INTERFERON; INTERFERON; INTERFERON RECEPTOR; INTERLEUKIN 12; INTERLEUKIN 29; MESSENGER RNA; MICRORNA; MICRORNA 155; MICRORNA 29; RNA BINDING PROTEIN; STAT1 PROTEIN; STAT2 PROTEIN; STAT4 PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

3' UNTRANSLATED REGION; ANTIVIRAL ACTIVITY; AU RICH ELEMENT; CYTOKINE PRODUCTION; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; RNA TRANSLATION; SIGNAL TRANSDUCTION; VIRUS REPLICATION; ANIMAL; METABOLISM;

ANIMALS; HUMANS; INTERFERONS; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION;

EID: 84900312836     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2013.0117     Document Type: Review

References (93)

1. Asirvatham AJ, Gregorie CJ, Hu Z, Magner WJ, Tomasi TB. 2008. MicroRNA targets in immune genes and the Dicer/ Argonaute and ARE machinery components. Mol Immunol 45(7):1995-2006.
2. Asirvatham AJ, Magner WJ, Tomasi TB. 2009. miRNA regulation of cytokine genes. Cytokine 45(2):58-69.
3. Asselin-Paturel C, Brizard G, Chemin K, Boonstra A, O'Garra A, Vicari A, Trinchieri G. 2005. Type I interferon dependence of plasmacytoid dendritic cell activation and migration. J Exp Med 201(7):1157-1167.
4. Asson-Batres MA, Spurgeon SL, Diaz J, DeLoughery TG, Bagby GC, Jr. 1994. Evolutionary conservation of the AUrich 3 untranslated region of messenger RNA. Proc Natl Acad Sci U S A 91(4):1318-1322.
5. Bach EA, Aguet M, Schreiber RD. 1997. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol 15:563-591.
6. Balagopal A, Thomas DL, Thio CL. 2010. IL28B and the control of hepatitis C virus infection. Gastroenterology 139(6): 1865-1876.
7. Banerjee A, Schambach F, DeJong CS, Hammond SM, Reiner SL. 2010. Micro-RNA-155 inhibits IFN-gamma signaling in CD4 + T cells. Eur J Immunol 40(1):225-231.
8. Bao M, Liu YJ. 2013. Regulation of TLR7/9 signaling in plasmacytoid dendritic cells. Protein Cell 4(1):40-52.
9. Bhanja Chowdhury J, Shrivastava S, Steele R, Di Bisceglie AM, Ray R, Ray RB. 2012. Hepatitis C virus infection modulates expression of interferon stimulatory gene IFITM1 by upregulating miR-130A. J Virol 86(18):10221-10225.
10. Buggele WA, Horvath CM. 2013. MicroRNA Profiling of Sendai Virus-Infected A549 Cells Identifies miR-203 as an Interferon-Inducible Regulator of IFIT1/ISG56. J Virol 87(16):9260-9270.
11. Chang CH, Curtis JD, Maggi LB, Faubert B, Villarino AV, O'Sullivan D, Huang SCC, van der Windt GJW, Blagih J, Qiu J, Weber JD, Pearce EJ, Jones RG, Pearce EL. 2013. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 153(6):1239-1251.
12. Chen CY, Shyu AB. 1995. AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem Sci 20(11):465-470.
13. Chen JM, Ferec C, Cooper DN. 2006. A systematic analysis of disease-associated variants in the 3 regulatory regions of human protein-coding genes II: the importance of mRNA secondary structure in assessing the functionality of 3 UTR variants. Hum Genet 120(3):301-333.
14. Cheng M, Si Y, Niu Y, Liu X, Li X, Zhao J, Jin Q, Yang W. 2013. High-throughput profiling of alpha interferon- and interleukin-28B-regulated microRNAs and identification of let-7s with anti-hepatitis C virus activity by targeting IGF2BP1. J Virol 87(17):9707-9718.
15. Cullen BR. 2006. Viruses and microRNAs. Nat Genet 38 Suppl:S25-S30.
16. David M. 2010. Interferons and microRNAs. J Interferon Cytokine Res 30(11):825-828.
17. de Weerd NA, Vivian JP, Nguyen TK, Mangan NE, Gould JA, Braniff SJ, Zaker-Tabrizi L, Fung KY, Forster SC, Beddoe T, Reid HH, Rossjohn J, Hertzog PJ. 2013. Structural basis of a unique interferon-beta signaling axis mediated via the receptor IFNAR1. Nat Immunol 14(9):901-907.
18. Donnelly RP, Kotenko SV. 2010. Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res 30(8): 555-564.
19. Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko SV, Renauld JC. 2004. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem 279(31):32269-32274.
20. Dunn GP, Koebel CM, Schreiber RD. 2006. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6(11): 836-848.
21. El-Ekiaby N, Hamdi N, Negm M, Ahmed R, Zekri AR, Esmat G, Abdelaziz AI. 2012. Repressed induction of interferonrelated microRNAs miR-146a and miR-155 in peripheral blood mononuclear cells infected with HCV genotype 4. FEBS Open Bio 2:179-186.
22. Fox BA, Sheppard PO, O'Hara PJ. 2009. The role of genomic data in the discovery, annotation and evolutionary interpretation of the interferon-lambda family. PLoS One 4(3): e4933.
23. Friborg J, Levine S, Chen CQ, Sheaffer AK, Chaniewski S, Voss S, Lemm JA, McPhee F. 2013. Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication. Antimicrob Agents Chemother 57(3):1312-1322.
24. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262):399-401.
25. Gibson SJ, Lindh JM, Riter TR, Gleason RM, Rogers LM, Fuller AE, Oesterich JL, Gorden KB, Qiu X, McKane SW, Noelle RJ, Miller RL, Kedl RM, Fitzgerald-Bocarsly P, Tomai MA, Vasilakos JP. 2002. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol 218(1-2):74-86.
26. Gil MP, Bohn E, O'Guin AK, Ramana CV, Levine B, Stark GR, Virgin HW, Schreiber RD. 2001. Biologic consequences of Stat1-independent IFN signaling. Proc Natl Acad Sci U S A 98(12):6680-6685.
27. Gillis P, Malter JS. 1991. The adenosine-uridine binding factor recognizes the AU-rich elements of cytokine, lymphokine, and oncogene mRNAs. J Biol Chem 266(5):3172-3177.
28. Gong BD, Xie Q, Xiang XG, Wang L, Zhao GD, An FM, Wang H, Lin LY, Yu H, Bao SS. 2010. Effect of ribavirin and interferon beta on miRNA profile in the hepatitis C virus subgenomic replicon-bearing Huh7 cells. Int J Mol Med 25(6):853-859.
29. Gonzalez-Navajas JM, Lee J, David M, Raz E. 2012. Immunomodulatory functions of type I interferons. Nat Rev Immunol 12(2):125-135.
30. Gracias DT, Stelekati E, Hope JL, Boesteanu AC, Doering TA, Norton J, Mueller YM, Fraietta JA, Wherry EJ, Turner M, Katsikis PD. 2013. The microRNA miR-155 controls CD8( + ) T cell responses by regulating interferon signaling. Nat Immunol 14(6):593-602.
31. Hamming OJ, Terczynska-Dyla E, Vieyres G, Dijkman R, Jorgensen SE, Akhtar H, Siupka P, Pietschmann T, Thiel V, Hartmann R. 2013. Interferon lambda 4 signals via the IFNlambda receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J 32(23):3055-3065.
32. Hariharan M, Scaria V, Pillai B, Brahmachari SK. 2005. Targets for human encoded microRNAs in HIV genes. Biochem Biophys Res Commun 337(4):1214-1218.
33. Hou J, Wang P, Lin L, Liu X, Ma F, An H, Wang Z, Cao X. 2009. MicroRNA-146a feedback inhibits RIG-I-dependent Type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2. J Immunol 183(3):2150-2158.
34. Hubert FX, Voisine C, Louvet C, Heslan M, Josien R. 2004. Rat plasmacytoid dendritic cells are an abundant subset of MHC class II + CD4 + CD11b-OX62- and type I IFN-producing cells that exhibit selective expression of Toll-like receptors 7 and 9 and strong responsiveness to CpG. J Immunol 172(12): 7485-7494.
35. Ikeda H, Old LJ, Schreiber RD. 2002. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 13(2):95-109.
36. Isaacs A, Lindenmann J. 1957. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 147(927):258-267.
37. Isaacs A, Lindenmann J, Valentine RC. 1957. Virus interference. II. Some properties of interferon. Proc R Soc Lond B Biol Sci 147(927):268-273.
38. Krug A, Towarowski A, Britsch S, Rothenfusser S, Hornung V, Bals R, Giese T, Engelmann H, Endres S, Krieg AM, Hartmann G. 2001. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 31(10):3026-3037.
39. Kulkarni S, Savan R, Qi Y, Gao X, Yuki Y, Bass SE, Martin MP, Hunt P, Deeks SG, Telenti A, Pereyra F, Goldstein D, Wolinsky S, Walker B, Young HA, Carrington M. 2011. Differential microRNA regulation of HLA-C expression and its association with HIV control. Nature 472(7344): 495-498.
40. Lau NC, Lim LP, Weinstein EG, Bartel DP. 2001. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 294(5543):858-862.
41. Lecellier CH, Dunoyer P, Arar K, Lehmann-Che J, Eyquem S, Himber C, Saib A, Voinnet O. 2005. A cellular microRNA mediates antiviral defense in human cells. Science 308(5721): 557-560.
42. Lee RC, Ambros V. 2001. An extensive class of small RNAs in Caenorhabditis elegans. Science 294(5543):862-864.
43. Li Y, Fan X, He X, Sun H, Zou Z, Yuan H, Xu H, Wang C, Shi X. 2012. MicroRNA-466l inhibits antiviral innate immune response by targeting interferon-alpha. Cell Mol Immunol 9(6):497-502.
44. Li Y, Xie J, Xu X, Wang J, Ao F, Wan Y, Zhu Y. 2013. MicroRNA-548 down-regulates host antiviral response via direct targeting of IFN-lambda1. Protein Cell 4(2):130-141.
45. Lodish HF, Zhou B, Liu G, Chen CZ. 2008. Micromanagement of the immune system by microRNAs. Nat Rev Immunol 8(2):120-130.
46. Ma F, Liu X, Li D, Wang P, Li N, Lu L, Cao X. 2010. MicroRNA- 466l upregulates IL-10 expression in TLR-triggered macrophages by antagonizing RNA-binding protein tristetraprolin- mediated IL-10 mRNA degradation. J Immunol 184(11):6053-6059.
47. Ma F, Xu S, Liu X, Zhang Q, Xu X, Liu M, Hua M, Li N, Yao H, Cao X. 2011. The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-gamma. Nat Immunol 12(9): 861-869.
48. McFarland AP, Horner SM, Jarret A, Joslyn RC, Bindewald E, Shapiro BA, Delker DA, Hagedorn CH, Carrington M, Gale M, Jr., Savan R. 2014. The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat Immunol 15(1): 72-79.
49. Meisner NC, Hackermuller J, Uhl V, Aszodi A, Jaritz M, Auer M. 2004. mRNA openers and closers: modulating AU-rich element-controlled mRNA stability by a molecular switch in mRNA secondary structure. Chembiochem 5(10):1432-1447.
50. Muljo SA, Ansel KM, Kanellopoulou C, Livingston DM, Rao A, Rajewsky K. 2005. Aberrant T cell differentiation in the absence of Dicer. J Exp Med 202(2):261-269.
51. Nagano Y, Kojima Y. 1958. [Interference of the inactive vaccinia virus with infection of skin by the active homologous virus]. C R Seances Soc Biol Fil 152(2):372-374.
52. Nathans R, Chu CY, Serquina AK, Lu CC, Cao H, Rana TM. 2009. Cellular microRNA and P bodies modulate host-HIV-1 interactions. Mol Cell 34(6):696-709.
53. O'Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. 2007. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A 104(5): 1604-1609.
54. Ogilvie RL, Sternjohn JR, Rattenbacher B, Vlasova IA, Williams DA, Hau HH, Blackshear PJ, Bohjanen PR. 2009. Tristetraprolin mediates interferon-gamma mRNA decay. J Biol Chem 284(17):11216-11223.
55. Otsuka M, Jing Q, Georgel P, New L, Chen J, Mols J, Kang YJ, Jiang Z, Du X, Cook R, Das SC, Pattnaik AK, Beutler B, Han J. 2007. Hypersusceptibility to vesicular stomatitis virus infection in Dicer1-deficient mice is due to impaired miR24 and miR93 expression. Immunity 27(1):123-134.
56. Ouda R, Onomoto K, Takahasi K, Edwards MR, Kato H, Yoneyama M, Fujita T. 2011. Retinoic acid-inducible gene I-inducible miR-23b inhibits infections by minor group rhinoviruses through down-regulation of the very low density lipoprotein receptor. J Biol Chem 286(29):26210-26219.
57. Papadopoulou AS, Dooley J, Linterman MA, Pierson W, Ucar O, Kyewski B, Zuklys S, Hollander GA, Matthys P, Gray DH, De Strooper B, Liston A. 2012. The thymic epithelial microRNA network elevates the threshold for infectionassociated thymic involution via miR-29a mediated suppression of the IFN-alpha receptor. Nat Immunol 13(2):181-187.
58. Paste M, Huez G, Kruys V. 2003. Deadenylation of interferonbeta mRNA is mediated by both the AU-rich element in the 3-untranslated region and an instability sequence in the coding region. Eur J Biochem 270(7):1590-1597.
59. Pedersen IM, Cheng G, Wieland S, Volinia S, Croce CM, Chisari FV, David M. 2007. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 449(7164): 919-922.
60. Pestka S. 2007. Purification and cloning of interferon alpha. Curr Top Microbiol Immunol 316:23-37.
61. Pott J, Mahlakoiv T, Mordstein M, Duerr CU, Michiels T, Stockinger S, Staeheli P, Hornef MW. 2011. IFN-lambda determines the intestinal epithelial antiviral host defense. Proc Natl Acad Sci U S A 108(19):7944-7949.
62. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, Hergott D, Porter-Gill P, Mumy A, Kohaar I, Chen S, Brand N, Tarway M, Liu L, Sheikh F, Astemborski J, Bonkovsky HL, Edlin BR, Howell CD, Morgan TR, Thomas DL, Rehermann B, Donnelly RP, O'Brien TR. 2013. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 45(2):164-171.
63. Pulaski BA, Smyth MJ, Ostrand-Rosenberg S. 2002. Interferongamma- dependent phagocytic cells are a critical component of innate immunity against metastatic mammary carcinoma. Cancer Res 62(15):4406-4412.
64. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF, Furrer H, Gunthard HF, Heim M, Hirschel B, Malinverni R, Moradpour D, Mullhaupt B, Witteck A, Beckmann JS, Berg T, Bergmann S, Negro F, Telenti A, Bochud PY, Swiss Hepatitis CCS, Swiss HIVCS. 2010. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138(4):1338-1345, 1345 e1-e7.
65. Reinsbach S, Nazarov PV, Philippidou D, Schmitt M, Wienecke- Baldacchino A, Muller A, Vallar L, Behrmann I, Kreis S. 2012. Dynamic regulation of microRNA expression following interferon-gamma-induced gene transcription. RNA Biol 9(7):978-989.
66. Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W. 2009. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med 15(1):31-33.
67. Savan R, Ravichandran S, Collins JR, Sakai M, Young HA. 2009. Structural conservation of interferon gamma among vertebrates. Cytokine Growth Factor Rev 20(2):115-124.
68. Scaria V, Hariharan M, Maiti S, Pillai B, Brahmachari SK. 2006. Host-virus interaction: a new role for microRNAs. Retrovirology 3:68.
69. Sedger LM. 2013. microRNA control of interferons and interferon induced anti-viral activity. Mol Immunol 56(4): 781-793.
70. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM. 2003. IL-28, IL-29 and their class II cytokine receptor IL- 28R. Nat Immunol 4(1):63-68.
71. Smith KM, Guerau-de-Arellano M, Costinean S, Williams JL, Bottoni A, Mavrikis Cox G, Satoskar AR, Croce CM, Racke MK, Lovett-Racke AE, Whitacre CC. 2012. miR-29ab1 deficiency identifies a negative feedback loop controlling Th1 bias that is dysregulated in multiple sclerosis. J Immunol 189(4):1567-1576.
72. Song L, Liu H, Gao S, Jiang W, Huang W. 2010. Cellular microRNAs inhibit replication of the H1N1 influenza A virus in infected cells. J Virol 84(17):8849-8860.
73. Steiner DF, Thomas MF, Hu JK, Yang Z, Babiarz JE, Allen CD, Matloubian M, Blelloch R, Ansel KM. 2011. MicroRNA-29 regulates T-box transcription factors and interferon-gamma production in helper T cells. Immunity 35(2):169-181.
74. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Muller T, Bahlo M, Stewart GJ, Booth DR, George J. 2009. IL28B is associated with response to chronic hepatitis C interferonalpha and ribavirin therapy. Nat Genet 41(10):1100-1104.
75. Taganov KD, Boldin MP, Baltimore D. 2007. MicroRNAs and immunity: tiny players in a big field. Immunity 26(2):133-137.
76. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. 2009. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41(10): 1105-1109.
77. Tang Y, Luo X, Cui H, Ni X, Yuan M, Guo Y, Huang X, Zhou H, de Vries N, Tak PP, Chen S, Shen N. 2009. MicroRNA- 146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 60(4):1065-1075.
78. Taylor GA, Carballo E, Lee DM, Lai WS, Thompson MJ, Patel DD, Schenkman DI, Gilkeson GS, Broxmeyer HE, Haynes BF, Blackshear PJ. 1996. A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Immunity 4(5):445-454.
79. Taylor KE, Mossman KL. 2013. Recent advances in understanding viral evasion of type I interferon. Immunology 138(3): 190-197.
80. Trotta R, Chen L, Ciarlariello D, Josyula S, Mao C, Costinean S, Yu L, Butchar JP, Tridandapani S, Croce CM, Caligiuri MA. 2012. miR-155 regulates IFN-gamma production in natural killer cells. Blood 119(15):3478-3485.
81. Vasudevan S, Tong Y, Steitz JA. 2007. Switching from repression to activation: microRNAs can up-regulate translation. Science 318(5858):1931-1934.
82. Vilcek J, Havell EA. 1973. Stabilization of interferon messenger RNA activity by treatment of cells with metabolic inhibitors and lowering of the incubation temperature. Proc Natl Acad Sci U S A 70(12):3909-3913.
83. Vilcek J, Jahiel RI. 1970. Action of interferon and its inducers aginst nonviral infectious agents. Arch Intern Med 126(1): 69-77.
84. Vilcek J, Ng MH. 1971. Post-transcriptional control of interferon synthesis. J Virol 7(5):588-594.
85. Vilcek J, Rossman TG, Varacalli F. 1969. Differential effects of actinomycin D and puromycin on the release of interferon induced by double stranded RNA. Nature 222(5194):682-683.
86. Villarino AV, Gallo E, Abbas AK. 2010. STAT1-activating cytokines limit Th17 responses through both T-bet-dependent and -independent mechanisms. J Immunol 185(11):6461-6471.
87. Whittemore LA, Maniatis T. 1990. Postinduction repression of the beta-interferon gene is mediated through two positive regulatory domains. Proc Natl Acad Sci U S A 87(20):7799-7803.
88. Witwer KW, Sisk JM, Gama L, Clements JE. 2010. MicroRNA regulation of IFN-beta protein expression: rapid and sensitive modulation of the innate immune response. J Immunol 184(5):2369-2376.
89. Young HA, Bream JH. 2007. IFN-gamma: recent advances in understanding regulation of expression, biological functions, and clinical applications. Curr Top Microbiol Immunol 316:97-117.
90. Zhang C, Han L, Zhang A, Yang W, Zhou X, Pu P, Du Y, Zeng H, Kang C. 2010. Global changes of mRNA expression reveals an increased activity of the interferon-induced signal transducer and activator of transcription (STAT) pathway by repression of miR-221/222 in glioblastoma U251 cells. Int J Oncol 36(6):1503-1512.
91. Zhang J, Zhao H, Chen J, Xia B, Jin Y, Wei W, Shen J, Huang Y. 2012. Interferon-beta-induced miR-155 inhibits osteoclast differentiation by targeting SOCS1 and MITF. FEBS Lett 586(19):3255-3262.
92. Zhou C, Yu Q, Chen L, Wang J, Zheng S, Zhang J. 2012. A miR-1231 binding site polymorphism in the 3 UTR of IFNAR1 is associated with hepatocellular carcinoma susceptibility. Gene 507(1):95-98.
93. Zhou H, Huang X, Cui H, Luo X, Tang Y, Chen S, Wu L, Shen N. 2010. miR-155 and its star-form partner miR-155* cooperatively regulate type I interferon production by human plasmacytoid dendritic cells. Blood 116(26):5885-5894.